newsfilter
← Latest News
GlobeNewswire·

Genenta Provides First Half 2022 Business Update and Financial Results

Current dose escalation study data shows a median overall survival of 17 monthsAdding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimenCash and cash equivalents of €34.7 million as of June 30,